Global menu

Our global pages


Eversheds comment: Japanese investment through Sun Pharmaceuticals deal will raise Indian concerns

  • United Kingdom


    Commenting on Sun Pharmaceuticals' acquisition of Ranbaxy, Parmjit Singh, head of India business group at global law firm Eversheds, comments:

    “Many in India will be concerned to see this announcement. Many see investment by Japanese companies as key to improving FDI flows into India and help grow domestic GDP. Is this an indication that doing business in India is too difficult or was this simply an offer too good for Japan's Daiichi Sankyo to turn down? Will other investors follow? Only time will tell.

    “Expect the opposition party, BJP to make a lot of this news in a country which went to the polls today for national elections. BJP have been openly critical of the ruling National Party for not being business friendly.”

    This information is for guidance purposes only and should not be regarded as a substitute for taking legal advice. Please refer to the full terms and conditions on our website.

    < Go back